Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
Xpert MTB/RIF is approved for use in tuberculosis (TB) and rifampicin-resistance diagnosis. However, data are limited on the impact of Xpert under routine conditions in settings with high TB burden.A pragmatic prospective cluster-randomised trial of Xpert for all individuals with presumptive (sympto...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-11-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC4244039?pdf=render |